EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial

Körperliche Aktivität ist mit der Belastbarkeit bei Patient:innen unter Chemotherapie assoziiert: Pilot-RCT

Alexis Antonucci iD, Alexander R Lucas iD, Juliana Costa, Sam Norton, Peter Brubaker, Shannon Mihalko, Alexandra Marshall, Jeremy Via iD, R Lee Franco, Amy Ladd, Rakhee Vaidya, Victor Yazbeck und 2 weitere

PLOS One · 29.09.2025 · 20 (9) · e0329774

DOI: 10.1371/journal.pone.0329774 ↗

Auf einen Blick

In einer Pilotstudie bei 33 Patient:innen mit Brustkrebs oder Lymphom waren körperliche Aktivität und 6-Minuten-Gehtest über 6 Monate weitgehend erhalten. Schritte/Tag waren nach 3 Monaten mit der 6-Minuten-Gehstrecke assoziiert.

Fragestellung

Wirkt eine 6-monatige körperliche Aktivitätsintervention im Vergleich zu gesundheitsbezogener Lebensstilaufklärung auf körperliche Aktivität und die submaximale Belastbarkeit bei Patient:innen unter potenziell kardiotoxischer Therapie?

Methode

Pilot-RCT mit Randomisierung 2:1 zu PAI oder HLI; objektive Messung von Schritten/Tag, MVPA/Woche und 6MWD zu Baseline, nach 3 und 6 Monaten.

Ergebnisse

33 Teilnehmende mit Brustkrebs oder Lymphom. Nach 3 und 6 Monaten bestand ein Unterschied in der 6MWD von 87 m bzw. 76 m zugunsten der Intervention. Schritte/Tag und 6MWD waren nach 3 Monaten korreliert (r = 0,51; p = .04).

Einschränkungen

Kleine Pilotstudie; nur deskriptive Auswertung und t-Tests; kein statistisch signifikanter Gruppenunterschied bei der 6MWD.

Schlussfolgerung der Autor:innen

Die Ausgangsdaten zeigen, dass die Stichprobe im Mittel nahe an den Empfehlungen für körperliche Aktivität lag. Höhere Aktivität könnte mit weniger Belastungsintoleranz nach Anthrazyklintherapie assoziiert sein.

Kernaussagen

  • 33 Patient:innen mit Brustkrebs oder Lymphom
  • Schritte/Tag mit 6MWD nach 3 Monaten assoziiert (r = 0,51)
  • 6MWD blieb über 6 Monate erhalten; Vorteil für PAI klinisch relevant, aber nicht signifikant

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, online erschienen am 29.09.2025. Verfasst von Alexis Antonucci und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States of America. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Exercise, Exercise Tolerance. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute (NCI).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Exercise intolerance is common among cancer patients undergoing active treatments. We conducted a pilot study in patients receiving potentially cardiotoxic therapies to investigate the impact of participation in a 6-month physical activity intervention (PAI) versus a healthy lifestyle education control intervention (HLI) on accelerometer-derived measures of PA (steps/day or minutes of moderate to vigorous PA [MVPA]/week) and whether these measures were associated with submaximal exercise capacity (6-minute walk distance [6MWD]).

Methods

Participants with breast cancer or lymphoma (n = 33) were randomized (2:1) into PAI or HLI groups. Exercise training was patient-centered, tailored by treatment and functional status. Objective assessments of PA (steps/day, MVPA/week), and submaximal exercise capacity (6MWD) were completed at baseline, 3-, and 6-months. Descriptive statistics were used to examine changes in PA and 6MWD. T-tests were used to examine differences in 6MWD between groups at 3- and 6-months.

Results

At baseline, 27 participants in the PAI (n = 20) and HLI (n = 7) groups who completed baseline and at least 1 follow up visit, had a mean age of 53 (range: 23–76) vs 56 (range: 40–77) years, took on average 8,330 ± 2520 vs 7800 ± 3830 steps/day, did an average of 133 ± 44 vs 109 ± 87 minutes of MVPA/week, and had a mean 6MWD of 496 ± 94 vs 440 ± 18 meters, respectively. At 3- and 6-months there was a 87m and 76m difference in 6MWD by intervention group. A correlation analysis did find significant associations between steps/day (r = 0.51, p = .04) and 6MWD at 3-months.

Conclusions

Baseline data indicate that, on average, our study sample was close to meeting the PA guidelines. Unexpectedly, both groups maintained their activity levels up to 3- and 6-months. Submaximal exercise capacity (6MWD) was also maintained (with a clinically meaningful but not statistically significant relative benefit in the PAI) suggesting higher PA levels may associate with reduced exercise intolerance after anthracycline therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBreast NeoplasmsExerciseExercise ToleranceLymphomaAdultAgedFemaleHumansMaleMiddle AgedExercise TherapyPilot Projects

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • School of Medicine, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Department of Internal Medicine, Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Department of Social and Behavioral Sciences, School of Public Health, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina, United States of America.
  • Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Department of Hematology and Oncology, Wake Forest University, Winston-Salem, North Carolina, United States of America.

ORCID-Profile: Alexis Antonucci, Alexander R Lucas, Jeremy Via

Förderung

  • National Cancer Institute (NCI)

Zitieren

APA

Antonucci, A., Lucas, A. R., Costa, J., Norton, S., Brubaker, P., Mihalko, S., Marshall, A., Via, J., Franco, R. L., Ladd, A., Vaidya, R., Yazbeck, V., Wagner, L., & Hundley, W. G. (2025). Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial. PLOS One, 20(9), e0329774. https://doi.org/10.1371/journal.pone.0329774

Vancouver

Antonucci A, Lucas AR, Costa J, Norton S, Brubaker P, Mihalko S, et al. Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial. PLOS One. 2025;20(9):e0329774. doi:10.1371/journal.pone.0329774

BibTeX
@article{Antonucci2025,
  author = {Antonucci, Alexis and Lucas, Alexander R and Costa, Juliana and Norton, Sam and Brubaker, Peter and Mihalko, Shannon and Marshall, Alexandra and Via, Jeremy and Franco, R Lee and Ladd, Amy and Vaidya, Rakhee and Yazbeck, Victor and Wagner, Lynne and Hundley, W Gregory},
  title = {Physical activity is associated with exercise capacity among patients undergoing chemotherapy: A pilot randomized controlled trial},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {9},
  pages = {e0329774},
  doi = {10.1371/journal.pone.0329774}
}
Kostenlos starten →